Corindus Wins Frost & Sullivan New Product Innovation Award

Corindus Vascular Robotics Inc. received Frost & Sullivan’s 2014 North American New Product Innovation Award in interventional cardiology. The award was established by industry consulting and research firm Frost & Sullivan to recognize visionary innovation and product excellence.

Corindus’s CorPath Vascular Robotic System, company officials claim, is the first medical device to bring robotic precision and accuracy to coronary angioplasty procedures, which may improve clinical outcomes while increasing radiation protection for interventional cardiologists.

“To achieve excellence in new product innovation leadership is not an easy task, but the CorPath system addresses a critical concern of interventional cardiologists, and has the potential to improve outcomes and economics in coronary angioplasty,” said Greg Caressi, senior vice president, Healthcare and Life Sciences, Frost & Sullivan. “Corindus’s receipt of this award signifies a great accomplishment.”

According to Caressi, the CorPath System stood out from other products in the market with the following key differentiators:

• Fulfilling unmet needs in interventional cardiology. The CorPath System is designd to decrease key career-limiting issues that physicians tend to face as a result of radiation exposure.

• Optimized design considerations for cath lab use. CorPath Is designed to have the physician sitting in the interventional cockpit, removed from radiation, in a robotic control unit that sits beside the patient on the patient table bedrail.

• Advancing care and safety. The CorPath System can navigate through the vascular anatomy to perform balloon stenting techniques.

• Innovative “One Stent” program. Corindus Vascular Robotics launched the CorPath One Stent Program to highlight the precision and accuracy of the CorPath System by offering a $1,000 credit to hospitals that use two or more stents per lesion in coronary angioplasties performed with CorPath.

• Future promise. The CorPath System is believed to have a future in emerging interventional techniques and could be leveraged for procedures in other related fields.

Corindus CEO David Handler said: “We are committed to pioneering a positive change in the delivery of healthcare and making a significant difference for patients, physicians and hospitals. Frost & Sullivan has validated that the direction we’re moving in is the right one. On behalf of Corindus, we would like to express our thanks for this esteemed honor.”

Waltham, Mass.-based Corindus Vascular Robotics makes technology for robotic-assisted percutaneous coronary interventions (PCIs). The CorPath 200 System, which has been cleared by the U.S. Food and Drug Administration, offers interventional cardiologists PCI procedure control from an interventional cockpit.